Literature DB >> 7023517

Role of calcium antagonists in cardiovascular therapy.

H Dargie, E Rowland, D Krikler.   

Abstract

The development of drugs which selectively block the "slow" channels by which calcium enters the cell (calcium antagonists) has provided valuable information about the role of transmembrane calcium exchange in man and has offered new therapeutic approaches. The principal effect on the cardiovascular system is relaxation of vascular smooth muscle but some of these drugs also have electrophysiological effects, especially slowing of conduction in the atrioventricular node; verapamil is the agent of choice in supraventricular tachycardia. Significant myocardial depression does not usually occur with doses used clinically. The calcium antagonists have specific value in variant angina. By causing peripheral vasodilatation they are also effective hypotensive agents and do not cause reflex tachycardia in chronic use. Their value in hypertrophic cardiomyopathy and in the protection of ischaemic myocardium remains to be proven.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7023517      PMCID: PMC482595          DOI: 10.1136/hrt.46.1.8

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  79 in total

Review 1.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

2.  Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog.

Authors:  D P Zipes; J C Fischer
Journal:  Circ Res       Date:  1974-02       Impact factor: 17.367

3.  Drugs and the heart. III. Calcium antagonists.

Authors:  L H Opie
Journal:  Lancet       Date:  1980-04-12       Impact factor: 79.321

4.  Haemodynamic effects of intravenous verapamil at rest and during exercise in subjectively healthy middle-aged men.

Authors:  J H Atterhög; L G Ekelund
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

5.  Membrane calcium current in ventricular myocardial fibres.

Authors:  G W Beeler; H Reuter
Journal:  J Physiol       Date:  1970-03       Impact factor: 5.182

6.  The beneficial effects of verapamil in chronic atrial fibrillation.

Authors:  H O Klein; H Pauzner; E Di Segni; D David; E Kaplinsky
Journal:  Arch Intern Med       Date:  1979-07

7.  Reentrant ventricular arrhythmias in the late myocardial infarction period. 7. Effect of verapamil and D-600 and the role of the "slow channel".

Authors:  N El-Sherif; R Lazzara
Journal:  Circulation       Date:  1979-09       Impact factor: 29.690

8.  Hypotensive action and increased plasma renin activity by Ca2+ antagonist (Nifedipine) in hypertensive patients.

Authors:  K Aoki; T Yoshida; S Kato; K Tazumi; I Sato
Journal:  Jpn Heart J       Date:  1976-07

9.  Pharmacological protection of mitochondrial function in hypoxic heart muscle: Effect of verapamil, propranolol, and methylprednisolone.

Authors:  W G Nayler; E Fassold; C Yepez
Journal:  Cardiovasc Res       Date:  1978-03       Impact factor: 10.787

10.  Nifedipine therapy for coronary-artery spasm. Experience in 127 patients.

Authors:  E Antman; J Muller; S Goldberg; R MacAlpin; M Rubenfire; B Tabatznik; C S Liang; F Heupler; S Achuff; N Reichek; E Geltman; N Z Kerin; R K Neff; E Braunwald
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

View more
  10 in total

1.  A haemodynamic and radionuclide assessment of diltiazem in coronary heart disease.

Authors:  B Silke; S K Sharma; S P Verma; K A Midtbo; G Reynolds; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

2.  The acute effects of nifedipine on red cell deformability in angina pectoris.

Authors:  D G Waller; H P Nicholson; S Roath
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

3.  Haemodynamic dose-response effects of i.v. nicardipine in coronary artery disease.

Authors:  B Silke; S P Verma; G I Nelson; M Hussain; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

4.  Calcium-channel blockers and asthma.

Authors:  P J Barnes
Journal:  Thorax       Date:  1983-07       Impact factor: 9.139

Review 5.  Calcium antagonists. Clinical use in the treatment of arrhythmias.

Authors:  B N Singh; K Nademanee; S H Baky
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

Review 6.  Beta-blockers and calcium antagonists in angina pectoris. The potential role of combination therapy.

Authors:  H J Dargie
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  Treatment of angina pectoris with nifedipine: importance of dose titration.

Authors:  J Deanfield; C Wright; K Fox
Journal:  Br Med J (Clin Res Ed)       Date:  1983-05-07

Review 8.  Combination therapy with beta-adrenoceptor blockers and calcium antagonists.

Authors:  H J Dargie
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 9.  Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.

Authors:  Rashmi R Shah; Peter D Stonier
Journal:  Ther Adv Drug Saf       Date:  2018-06-18

10.  Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.

Authors:  Faris Zvizdic; Edin Begic; Aida Mujakovic; Enisa Hodzic; Besim Prnjavorac; Omer Bedak; Faruk Custovic; Haris Bradaric; Azra Durak-Nalbantic
Journal:  Med Arch       Date:  2019-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.